BEAT - BioTelemetry: A Strong Buy At 52-Week Lows As A Key Part Of Apple's Heart Study Innovation
BioTelemetry Inc. (BEAT) continues to grow as a key partner in Apple Inc.'s (AAPL) Heart Study as Apple continues to rely more and more on its services to bring in additional revenue. Biotelemetry continues to grow at an impressive rate as it continues to absorb other companies that quickly add to its core strengths and abilities. Medicare headwinds and shrinking margins are not stopping the company from putting up double digit growth quarter after quarter as it effectively deals with adversity even near 52-week lows.
Apple's Heart Study is being conducted